Thursday, October 31, 2024 10:53:21 AM
Does anyone seriously understand the significance of their results?
You could have had this at $3.50.
Market red and ELDN shows incredible strength.
I think it can actually break $4.50 today on a crappy day.
That must say something about the interest In this stock.
Hello? Anyone out there? Lol
You could have had this at $3.50.
Market red and ELDN shows incredible strength.
I think it can actually break $4.50 today on a crappy day.
That must say something about the interest In this stock.
Hello? Anyone out there? Lol
Recent ELDN News
- Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine • GlobeNewswire Inc. • 06/08/2026 11:00:00 AM
- Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions • GlobeNewswire Inc. • 06/04/2026 08:31:28 PM
- Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress • GlobeNewswire Inc. • 05/20/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:15:17 PM
- Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/13/2026 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/12/2026 04:15:11 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/01/2026 08:08:43 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:04:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:57:13 PM
- NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 • GlobeNewswire Inc. • 04/30/2026 12:15:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/27/2026 08:12:23 PM
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results • GlobeNewswire Inc. • 03/19/2026 09:10:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2026 09:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 09:02:09 PM
- Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation • GlobeNewswire Inc. • 03/10/2026 11:00:00 AM
- Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/04/2026 09:05:00 PM
- Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 • GlobeNewswire Inc. • 02/05/2026 09:10:11 PM
- Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium • GlobeNewswire Inc. • 01/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 10:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 10:00:07 PM
